Biktarvy demonstrates consistent real-world efficacy for patients with HIV

0

The study also gathered patient-reported results in routine clinical practice to understand the effects of treatment on health-related quality of life.

Interim results from Gilead’s ongoing, multinational, real-world, single-arm, non-comparative, observational, cohort BICSTaR trial evaluating Biktarvy (bictegravir 50 mg / emtricitabine 200 mg / tenofovir alafenamide 25 mg tablets, B / F / TAF) in patients with proven HIV that 97% of therapy-naive adults and 96% of therapy-experienced adults achieved and maintained virological suppression after 1 year of treatment. The study also gathered patient-reported results in routine clinical practice to understand the effects of treatment on health-related quality of life.

“Despite advances in antiretroviral therapy, people with HIV experience distressing multidimensional symptoms and concerns that require person-centered care,” said Fernando Bognar, MD, Gilead Sciences vice president of medical affairs, HIV, in a press release. “The patient-reported results observed in the BICSTaR trial provide a first-hand assessment of the impact of HIV treatment and care on the quality of life of people living with HIV. Because doctors and people living with HIV want to understand what long-term treatment means for them personally, these data are below [European AIDS Conference 2021] also affirm that Biktarvy can address the specific treatment needs of different groups of people, including men and women aging with HIV and those with existing comorbid conditions. “

The study population included adults aged 50 and over, cisgender women, and late presenters. Biktarvy was generally well tolerated, with 13% of patients experiencing adverse events (AEs) and less than 1% of patients experiencing serious AEs. The most common side effects were weight gain (3%), nausea (1%), depression (1%), headache (1%), fatigue (1%), diarrhea (1%) and insomnia (1%).

Throughout the BICSTaR study, participants who started treatment with Biktarvy between June 2018 and September 2020 completed questionnaires at baseline and after 12 months. These questionnaires are designed to assess patient-reported results, which cover a range of interventions.


Source link

Share.

Leave A Reply